NON-CONTROLLING INTEREST

12 Months Ended

Mar. 31, 2026

Notes and other explanatory information [abstract]

NON-CONTROLLING INTEREST

NOTE 24. NON-CONTROLLING INTEREST

The table below summarize the Company’s non-controlling interest as of the periods presented (in thousands):


			Saugatuck and subsidary
Non-controlling interest as of April 1, 2023		$	(650	)
Net loss attributable to non-controlling interest			(43	)
Non-controlling interest as of March 31, 2024		$	(693	)
Net loss attributable to non-controlling interest			(11	)
Non-controlling interest as of March 31, 2025		$	(704	)
Net loss attributable to non-controlling interest			(1	)
Non-controlling interest as of March 31, 2026		$	(705	)

The Company held 70% interest in Saugatuck and subsidiary through SalvaRx. Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.